Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Vehicle Recompete: Bpa 75H71222A00004

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract pertains to a vehicle BPA (Blanket Purchase Agreement) identified as 75H71222A00004, managed by the Phoenix Area Indian Health Service under the Department of Health and Human Services. The ordering period for this BPA runs until June 30, 2027, with a total IDV ceiling amounting to $431,473. Currently, there are no active task orders associated with this BPA. The original solicitation for this contract was RFQ1550941, and it falls under the NAICS code 325413. The contract classification indicates a full recompete, with high confidence in this status. Key task orders related to this vehicle BPA include significant purchases by WERFEN USA LLC for IMMUCAR laboratory supplies, with values of approximately $86,295 and $68,078 respectively. These task orders demonstrate ongoing supply relationships managed under similar BPA call numbers. The contracting office responsible for the BPA is the Phoenix Area Indian Health Service, part of the Department of Health and Human Services, though specific location and contact details remain unspecified. This contract supports procurement needs related to health services, particularly within the scope of immunology and laboratory supplies.

General Info

Vehicle BPA 75H71222A00004 with $431,473 ceiling, active until June 2027, managed by Phoenix Area Indian Health Service.

Agency

Department Of Health And Human Services → Phoenix Area Indian Health SvcView Agency

NAICS

325413 - In-Vitro Diagnostic Substance ManufacturingView NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

pre-forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Phoenix Area Indian Health Svc
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → Phoenix Area Indian Health Svc
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Bpa vehicle 75H71222A00004 ordering period ends 2027-06-30T00:00:00.000Z. 0 active task orders valued at $0.
Pimc, bpa, immucor inc Original Solicitation: RFQ1550941 IDV Ceiling: $431,473 Contracting Office: Phoenix Area Indian Health Svc Agencies: Department of Health and Human Services Classification: full-recompete (Confidence: high - 85/100)
Top task orders by value: - WERFEN USA LLC, IMMUCAR LAB SUPPLIES, PIMC, BPA CALL 25F28004 ($86,294.6) - WERFEN USA LLC - PIMC, BPA CALL 75H71223F28002, IMMUCOR INC, IHS1468191 ($68,078.03) - WERFEN USA LLC

Similar Contracts

Same NAICS industry code

NAICS: 325413
New
Federal
Notice of Intent to Sole Source - Abbott Laboratories Inc. - Fort Jackson, SC
Solicitation # PANHCA26P0000031152_Modified
The Defense Health Agency Contracting Activity Healthcare Contracting Division, Southeast, has issued an updated Notice of Intent to Sole Source regarding a bilateral modification to an existing Firm-Fixed-Price, commercial Cost-Per-Reportable-Result contract. The government intends to award this out-of-scope modification to Abbott Laboratories, Inc. to support the Moncrief Army Health Clinic at Fort Jackson, South Carolina. The primary objective of this action is to increase estimated quantities and overall ceiling funding for option years one through four, covering chemistry and immunochemistry analyzers, reagents, consumables, calibrations, and control material in support of Defense Health Agency and Department of the Army missions. This notice is for informational purposes and does not constitute a formal solicitation or a request for competitive proposals. Under the determination that only one responsible source can satisfy the agency's requirements, any interested parties wishing to challenge this intent must provide clear, compelling, and convincing evidence that competition would be advantageous to the government. Interested and capable parties must submit a Capabilities Statement on company letterhead via email to the designated points of contact no later than 12:00 P.M. EDT on August 24, 2026. The requirement falls under NAICS code 325413 for in-vitro diagnostic substances manufacturing.
Defense Health Agency

POSTED

3 days ago

DEADLINE

in about 1 hour
View Details
NAICS: 325413
New
Federal
6550--INTENT TO SOLE SOURCE - Buffalo VA Thermo Fisher GENEXUS Reagents
Solicitation # 36C24226Q0938
The Department of Veterans Affairs, acting on behalf of the Buffalo VA Medical Center, intends to award a firm fixed price sole source contract to Thermo Fisher Scientific for the procurement of specialized reagents and supplies. These materials are essential for the Pathology and Laboratory Medicine Department to maintain patient testing on their existing Genexus instrument and Genexus Purification System. The procurement includes critical items such as the Oncomine Precision Assay, sequencing kits, barcodes, and purification kits, which facilitate comprehensive genomic profiling to assist healthcare providers in identifying actionable genetic alterations for cancer treatment. This notice serves as an intent to award and is not a request for quotes, though responsible sources may submit capability statements to demonstrate their ability to provide the required services. All submissions must be received by 10:00 AM Eastern Standard Time on August 27, 2025, and should be directed to the contracting officer. The government maintains strict prohibitions against the use of gray market items to ensure all supplies originate from the manufacturer's intended distribution channels. The agency reserves sole discretion in determining whether to proceed with the intended sole source award based on any received responses.
242-NETWORK Contract Office 02 (36C242)

POSTED

4 days ago

DEADLINE

in 3 days
View Details

More opportunities from Department Of Health And Human Services → Phoenix Area Indian Health Svc

Same awarding agency

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
Federal
Vehicle Recompete: Idc 75N95022D00017This contract is an indefinite delivery contract vehicle (IDC) with the identifier 75N95022D00017, overseeing the ordering period from September 5, 2022, through September 4, 2027. It supports the National Institute on Drug Abuse (NIDA) data, statistics, and clinical trial operations under the Department of Health and Human Services, managed by the National Institutes of Health (NIH). The contract has a ceiling value of approximately $44.3 million and does not involve any set-aside provisions. It represents a full recompete classification, indicating a competitive solicitation process to award the contract. Currently, there are no active task orders valued at zero, but several significant task orders have been executed under this vehicle. Several key task orders highlight the contract’s scope and value, all awarded to The Emmes Company, LLC. These task orders cover a variety of research and analytical services, including the management and support of the Data and Statistics Center (DSC) from March 2025 to February 2026 ($1.85 million), data analysis related to GLP-1 as an adjunct to buprenorphine from May 2025 to February 2028 ($1.4 million), and various other clinical and secondary analysis projects concerning opioid use disorder and related research, with task order values ranging from approximately $375,000 to $800,000. The work performed under these task orders reflects a comprehensive support framework for clinical trials and data management activities essential to advancing research efforts around drug abuse and treatment strategies.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

6 months ago

DEADLINE

N/A
View Details